0001104659-21-130909.txt : 20211201 0001104659-21-130909.hdr.sgml : 20211201 20211028134836 ACCESSION NUMBER: 0001104659-21-130909 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nabriva Therapeutics plc CENTRAL INDEX KEY: 0001641640 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L2 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 25-28 NORTH WALL QUAY CITY: DUBLIN STATE: L2 ZIP: D01 H104 BUSINESS PHONE: (610) 816-6640 MAIL ADDRESS: STREET 1: 414 COMMERCE DRIVE STREET 2: STE 120 CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Nabriva Therapeutics AG DATE OF NAME CHANGE: 20150507 CORRESP 1 filename1.htm

NABRIVA THERAPEUTICS PLC

25-28 North Wall Quay, IFSC

Dublin 1, Ireland

October 28, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re:	Nabriva Therapeutics plc
	Registration Statement on Form S-1
	File No. 333-260146
	Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nabriva Therapeutics plc (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-260146) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on November 1, 2021, or as soon thereafter as practicable.

	Very truly yours,

	NABRIVA THERAPEUTICS PLC

	By:	/s/ Theodore Schroeder
	Name:	Theodore Schroeder
	Title:	Chief Executive Officer

cc:	Brian A. Johnson
	Wilmer Cutler Pickering Hale and Dorr LLP